The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Bivalirudin versus Heparin Monotherapy in Myocardial Infarction
Open accessAbstract
BACKGROUNDThe comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use of radial-artery access for PCI and administration of potent P2Y 12 inhibitors without the planned use of glycoprotein IIb/IIIa inhibitors. METHODSIn this multicenter, randomized, registry-based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving treatment with a potent P2Y 12 inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glycoprotein IIb/IIIa inhibitors.The patients were randomly assigned to receive bivalirudin or heparin during PCI, which was performed predominantly with the use of radial-artery access.The primary end point was a composite of death from any cause, myocardial infarction, or major bleeding during 180 days of follow-up. RESULTSA total of 6006 patients (3005 with STEMI and 3001 with NSTEMI) were enrolled in the trial.At 180 days, a primary end-point event had occurred in 12.3% of the patients (369 of 3004) in the bivalirudin group and in 12.8% (383 of 3002) in the heparin group (hazard ratio, 0.96; 95% confidence interval [CI], 0.83 to 1.10; P = 0.54).The results were consistent between patients with STEMI and those with NSTEMI and across other major subgroups.Myocardial infarction occurred in 2.0% of the patients in the bivalirudin group and in 2.4% in the heparin group (hazard ratio, 0.84; 95% CI, 0.60 to 1.19; P = 0.33), major bleeding in 8.6% and 8.6%, respectively (hazard ratio, 1.00; 95% CI, 0.84 to 1.19; P = 0.98), definite stent thrombosis in 0.4% and 0.7%, respectively (hazard ratio, 0.54; 95% CI, 0.27 to 1.10; P = 0.09), and death in 2.9% and 2.8%, respectively (hazard ratio, 1.05; 95% CI, 0.78 to 1.41; P = 0.76). CONCLUSIONSAmong patients undergoing PCI for myocardial infarction, the rate of the composite of death from any cause, myocardial infarction, or major bleeding was not lower among those who received bivalirudin than among those who received heparin monotherapy.(Funded by the Swedish Heart-Lung Foundation and others; VALIDATE-SWEDEHEART Clinical-TrialsRegister.eu number, 2012-005260-10; ClinicalTrials.govnumber, NCT02311231.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Bivalirudin during Primary PCI in Acute Myocardial Infarction
Stone, G. W., Witzenbichler, B., Guagliumi, G., Peruga, J. Z., Brodie, B. R., Dudek, D., Kornowski, R., Hartmann, F., Gersh, B. J., Pocock, S. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708191 · Cited by 1,867
Bivalirudin for Patients with Acute Coronary Syndromes
Stone, G. W., McLaurin, B. T., Cox, D. A., Bertrand, M. E., Lincoff, A. M., Moses, J. W., White, H. D., Pocock, S. J., Ware, J. H., Feit, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062437 · Cited by 1,459
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes
Eikelboom, J. W., Mehta, S. R., Anand, S. S., Xie, C., Fox, K. A. A., & Yusuf, S. (2006) · Circulation · doi:10.1161/circulationaha.106.612812 · Cited by 1,341
Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction
Montalescot, G., Barragan, P., Wittenberg, O., Ecollan, P., Elhadad, S., Villain, P., Boulenc, J.-M., Morice, M.-C., Maillard, L., Pansiéri, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442503 · Cited by 1,186
Lincoff, A. M., Bittl, J. A., Harrington, R. A., Feit, F., Kleiman, N. S., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D., Ebrahimi, R., et al. (2003) · JAMA · doi:10.1001/jama.289.7.853 · Cited by 1,162
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Bhatt, D. L., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Steg, P. G., Hamm, C. W., Price, M. J., Leonardi, S., Gallup, D., Bramucci, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300815 · Cited by 840
Shahzad, A., Kemp, I., Mars, C., Wilson, K., Roome, C., Cooper, R., Andron, M., Appleby, C., Fisher, M., Khand, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60924-7 · Cited by 543
Bivalirudin Started during Emergency Transport for Primary PCI
Steg, P. G., van 't Hof, A., Hamm, C. W., Clemmensen, P., Lapostolle, F., Coste, P., Ten Berg, J., Van Grunsven, P., Eggink, G. J., Nibbe, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311096 · Cited by 498
Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes
Valgimigli, M., Frigoli, E., Leonardi, S., Rothenbühler, M., Gagnor, A., Calabrò, P., Garducci, S., Rubartelli, P., Briguori, C., Andò, G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507854 · Cited by 397
Self-citationMontalescot, G., Zeymer, U., Silvain, J., Boulanger, B., Cohen, M., Goldstein, P., Ecollan, P., Combes, X., Huber, K., Pollack, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60876-3 · Cited by 325
Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction
Kastrati, A., Neumann, F.-J., Schulz, S., Massberg, S., Byrne, R. A., Ferenc, M., Laugwitz, K.-L., Pache, J., Ott, I., Hausleiter, J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109596 · Cited by 314
Han, Y., Guo, J., Zheng, Y., Zang, H., Su, X., Wang, Y., Chen, S., Jiang, T., Yang, P., Chen, J., et al. (2015) · JAMA · doi:10.1001/jama.2015.2323 · Cited by 310
Dangas, G. D., Caixeta, A., Mehran, R., Parise, H., Lansky, A. J., Cristea, E., Brodie, B. R., Witzenbichler, B., Guagliumi, G., Peruga, J. Z., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.981688 · Cited by 248
Schulz, S., Richardt, G., Laugwitz, K., Morath, T., Neudecker, J., Hoppmann, P., Mehran, R., Gershlick, A., Tölg, R., Fiedler, K. A., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu182 · Cited by 108
Zeymer, U., Hof, A. W. J. V. ’., Adgey, J., Nibbe, L., Clemmensen, P. M., Cavallini, C., ten Berg, J. M., Coste, P., Huber, K., Deliargyris, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu214 · Cited by 92
Koutouzis, M., Lagerqvist, B., James, S. K., Ömerovic, E., Matejka, G., Grip, L., & Albertsson, P. (2011) · Heart · doi:10.1136/hrt.2011.224709 · Cited by 51
Self-citationErlinge, D., Koul, S. M., Eriksson, P., Scherstén, F., Ömerovic, E., Linder, R. B. A., Östlund, O. P., Wallentin, L. C., Fröbert, O., & James, S. K. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.02.007 · Cited by 44
Self-citation
Cited by
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citationCollet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Self-citation2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
Lawton, J. S., Tamis-Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.006 · Cited by 1,558
2018 ESC/EACTS Guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · EuroIntervention · doi:10.4244/eijy19m01_01 · Cited by 1,259
Metadata
- Authors
- Erlinge, D., Omerovic, E., Fröbert, O., Linder, R., Danielewicz, M., Hamid, M., Swahn, E., Henareh, L., Wagner, H., Hårdhammar, P., Sjögren, I., Stewart, J., Grimfjärd, P., Jensen, J., Aasa, M., Robertsson, L., Lindroos, P., Haupt, J., Wikström, H., Ulvenstam, A., Bhiladvala, P., Lindvall, B., Lundin, A., Tödt, T., Ioanes, D., Råmunddal, T., Kellerth, T., Zagozdzon, L., Götberg, M., Andersson, J., Angerås, O., Östlund, O., Lagerqvist, B., Held, C., Wallentin, L., Scherstén, F., Eriksson, P., Koul, S., & James, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-09-21
- Volume
- 377
- Issue
- 12
- Pages
- 1132-1142
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2745712984
- Cited by
- 301
- References
- 20
- FWCI
- 26.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.